Association of Self-Reported Depression on the Lupus Impact Tracker with Glucocorticoid Therapy and Fibromyalgia in Systemic Lupus Erythematosus: Insights from the RELESSER-PROS Registry - Scorecard - MDSpire
Advertisement
Association of Self-Reported Depression on the Lupus Impact Tracker with Glucocorticoid Therapy and Fibromyalgia in Systemic Lupus Erythematosus: Insights from the RELESSER-PROS Registry
Clinical Scorecard: Association of Self-Reported Depression on the Lupus Impact Tracker with Glucocorticoid Therapy and Fibromyalgia in Systemic Lupus Erythematosus: Insights from the RELESSER-PROS Registry
At a Glance
Category
Detail
Condition
Systemic lupus erythematosus (SLE)
Key Mechanisms
Autoimmune disease with heterogeneous manifestations; depression as a frequent neuropsychiatric symptom influenced by psychosocial and iatrogenic factors
Target Population
Patients with SLE enrolled in the RELESSER-PROS registry
Care Setting
Rheumatology outpatient clinics with routine clinical monitoring
Key Highlights
High prevalence of self-reported depression in SLE patients (89.9% any time; 34.6% most of the time).
Depression assessed via Lupus Impact Tracker item 7 (LITQ7) correlates well with clinical diagnosis.
Glucocorticoid use and fibromyalgia are associated with increased self-reported depressive symptoms over time.
Guideline-Based Recommendations
Diagnosis
Use patient-reported outcome measures like the Lupus Impact Tracker (LIT) to identify mood disturbances in SLE.
Consider LITQ7 responses as a proxy for self-perceived depression in clinical assessments.
Management
Monitor and address glucocorticoid therapy as a modifiable factor contributing to depression.
Evaluate and manage fibromyalgia comorbidity to potentially reduce depressive symptoms.
Incorporate patient perspectives to guide individualized treatment decisions.
Monitoring & Follow-up
Conduct annual protocolized evaluations including LITQ7 to track depressive symptoms longitudinally.
Assess disease activity (SELENA-SLEDAI), organ damage (SLICC/ACR Damage Index), and comorbidities regularly.
Monitor changes in glucocorticoid use and lifestyle factors influencing depression.
Risks
Persistent depressive symptoms are linked to greater organ damage and worse clinical outcomes.
Depression may reduce treatment adherence and quality of life, increasing morbidity and mortality.
Patient & Prescribing Data
SLE patients with a mean age of 55 years, predominantly female (90%), median disease duration 14 years
Glucocorticoid use ranged from 49.4% to 57% and was significantly associated with self-reported depression; fibromyalgia present in 5.7% also linked to depression.
Clinical Best Practices
Incorporate brief, validated PROMs like the Lupus Impact Tracker in routine SLE care to capture patient mood and disease impact.
Recognize and treat depression as a common and impactful comorbidity in SLE.
Address modifiable factors such as glucocorticoid dosing and fibromyalgia to improve mental health outcomes.
Use longitudinal patient-reported data to inform clinical decision-making and monitor treatment response.
by Inigo Rua-Figueroa, Julia Martínez-Barrio, Zulema Plaza, Norman Jiménez, Maria Galindo-Izquierdo, Esther Uriarte, Antonio Fernandez-Nebro, Jaime Calvo Alen, José Rosas, Javier Narváez, Elena Aurrecoechea, Mercedes Freire, Eva Tomero, Clara Sanguesa, Carlota Iniguez, Ana Perez, Sandra Garrote, Nuria Lozano-Rivas, Oihane Ibarguengoitia, Eva Salgado, Celia Erausquin, Tarek Carlos Salman Monte, Raúl Menor, Irene Altabás-González, Jorge Fragio Gil , Joan M. Nolla, Jose M. Pego-Reigosa
